These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29566768)

  • 1. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
    Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
    Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
    Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.
    Vizeacoumar FJ; Arnold R; Vizeacoumar FS; Chandrashekhar M; Buzina A; Young JT; Kwan JH; Sayad A; Mero P; Lawo S; Tanaka H; Brown KR; Baryshnikova A; Mak AB; Fedyshyn Y; Wang Y; Brito GC; Kasimer D; Makhnevych T; Ketela T; Datti A; Babu M; Emili A; Pelletier L; Wrana J; Wainberg Z; Kim PM; Rottapel R; O'Brien CA; Andrews B; Boone C; Moffat J
    Mol Syst Biol; 2013 Oct; 9():696. PubMed ID: 24104479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
    Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.
    Banerjee S; Buhrlage SJ; Huang HT; Deng X; Zhou W; Wang J; Traynor R; Prescott AR; Alessi DR; Gray NS
    Biochem J; 2014 Jan; 457(1):215-25. PubMed ID: 24171924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
    Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
    Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
    Telford BJ; Chen A; Beetham H; Frick J; Brew TP; Gould CM; Single A; Godwin T; Simpson KJ; Guilford P
    Mol Cancer Ther; 2015 May; 14(5):1213-23. PubMed ID: 25777964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional viability profiles of breast cancer.
    Brough R; Frankum JR; Sims D; Mackay A; Mendes-Pereira AM; Bajrami I; Costa-Cabral S; Rafiq R; Ahmad AS; Cerone MA; Natrajan R; Sharpe R; Shiu KK; Wetterskog D; Dedes KJ; Lambros MB; Rawjee T; Linardopoulos S; Reis-Filho JS; Turner NC; Lord CJ; Ashworth A
    Cancer Discov; 2011 Aug; 1(3):260-73. PubMed ID: 21984977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
    Srihari S; Singla J; Wong L; Ragan MA
    Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
    Kim EJ; Jeong JH; Bae S; Kang S; Kim CH; Lim YB
    J Cell Biochem; 2013 Jun; 114(6):1248-56. PubMed ID: 23592446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.
    Mereniuk TR; El Gendy MA; Mendes-Pereira AM; Lord CJ; Ghosh S; Foley E; Ashworth A; Weinfeld M
    Mol Cancer Ther; 2013 Oct; 12(10):2135-44. PubMed ID: 23883586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy.
    Ning L; Guo-Chun Z; Sheng-Li A; Xue-Rui L; Kun W; Jian Z; Chong-Yang R; Ling-Zhu W; Hai-Tong L
    Tumour Biol; 2016 Apr; 37(4):5445-54. PubMed ID: 26563373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal PTEN determines mammary epithelial response to radiotherapy.
    Sizemore GM; Balakrishnan S; Thies KA; Hammer AM; Sizemore ST; Trimboli AJ; Cuitiño MC; Steck SA; Tozbikian G; Kladney RD; Shinde N; Das M; Park D; Majumder S; Krishnan S; Yu L; Fernandez SA; Chakravarti A; Shields PG; White JR; Yee LD; Rosol TJ; Ludwig T; Park M; Leone G; Ostrowski MC
    Nat Commun; 2018 Jul; 9(1):2783. PubMed ID: 30018330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA‑142‑5p modulates breast cancer cell proliferation and apoptosis by targeting phosphatase and tensin homolog.
    Xu W; Wang W
    Mol Med Rep; 2018 Jun; 17(6):7529-7536. PubMed ID: 29620260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.
    Nakanishi Y; Walter K; Spoerke JM; O'Brien C; Huw LY; Hampton GM; Lackner MR
    Cancer Res; 2016 Mar; 76(5):1193-203. PubMed ID: 26759240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer.
    Zhou XJ; Wu J; Shi L; Li XX; Zhu L; Sun X; Qian JY; Wang Y; Wei JF; Ding Q
    J Exp Clin Cancer Res; 2017 Oct; 36(1):149. PubMed ID: 29052531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.